The role of proteasome in malignant diseases

Eva Moran, Alessio Nencioni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Proteasomal degradation is the main mechanism accounting for intracellular protein degradation. Not only is the proteasome involved in physiological protein turnover it is also calledintoplay by processes such as signal transduction, cell cycle, and apoptosis. Despite the ubiquitous distribution of the proteasome and its putative essential function, proteasome inhibitors have been developed that can be safely administered with acceptable side effects. Importantly, these compounds have been found to possess anti tumor activity and are presently incorporated into the treatment of multiple myeloma and mantle cell lymphoma. In 2003, bortezomib (velcade) was thefirst compound in this category to have received FDA approval. The mechanisms for the antitumor activity of bortezomib and related drugs remain elusive. NF-κB inhibition by proteasome inhibitors may play a role in some instances. Recently, terminally differentiated plasma cells have been shown to down regulate proteasome expression and overall proteasome activity, which may account for the exquisite susceptibility of multiple myeloma cells to proteasome inhibition. New proteasome inhibitors with improved pharmacological properties are being developed and will soon enter clinical experimentation. Finally, studies addressing the usefulness ofthese compounds in other types of malignancies are ongoing and may soon expand the number of applications of these new therapeutic agents.

Original languageEnglish
JournalJournal of B.U.ON.
Volume12
Issue numberSUPPL. 1
Publication statusPublished - Sep 2007

Fingerprint

Proteasome Endopeptidase Complex
Proteasome Inhibitors
Multiple Myeloma
Mantle-Cell Lymphoma
Plasma Cells
Proteolysis
Signal Transduction
Neoplasms
Cell Cycle
Down-Regulation
Pharmacology
Apoptosis
Pharmaceutical Preparations
Bortezomib
Proteins

Keywords

  • Apoptosis
  • Cancer
  • Multiple myeloma
  • NF-κB
  • Proteasome inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of proteasome in malignant diseases. / Moran, Eva; Nencioni, Alessio.

In: Journal of B.U.ON., Vol. 12, No. SUPPL. 1, 09.2007.

Research output: Contribution to journalArticle

@article{519c449a9ba340a1adf6fb9eaec117b6,
title = "The role of proteasome in malignant diseases",
abstract = "Proteasomal degradation is the main mechanism accounting for intracellular protein degradation. Not only is the proteasome involved in physiological protein turnover it is also calledintoplay by processes such as signal transduction, cell cycle, and apoptosis. Despite the ubiquitous distribution of the proteasome and its putative essential function, proteasome inhibitors have been developed that can be safely administered with acceptable side effects. Importantly, these compounds have been found to possess anti tumor activity and are presently incorporated into the treatment of multiple myeloma and mantle cell lymphoma. In 2003, bortezomib (velcade) was thefirst compound in this category to have received FDA approval. The mechanisms for the antitumor activity of bortezomib and related drugs remain elusive. NF-κB inhibition by proteasome inhibitors may play a role in some instances. Recently, terminally differentiated plasma cells have been shown to down regulate proteasome expression and overall proteasome activity, which may account for the exquisite susceptibility of multiple myeloma cells to proteasome inhibition. New proteasome inhibitors with improved pharmacological properties are being developed and will soon enter clinical experimentation. Finally, studies addressing the usefulness ofthese compounds in other types of malignancies are ongoing and may soon expand the number of applications of these new therapeutic agents.",
keywords = "Apoptosis, Cancer, Multiple myeloma, NF-κB, Proteasome inhibitors",
author = "Eva Moran and Alessio Nencioni",
year = "2007",
month = "9",
language = "English",
volume = "12",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The role of proteasome in malignant diseases

AU - Moran, Eva

AU - Nencioni, Alessio

PY - 2007/9

Y1 - 2007/9

N2 - Proteasomal degradation is the main mechanism accounting for intracellular protein degradation. Not only is the proteasome involved in physiological protein turnover it is also calledintoplay by processes such as signal transduction, cell cycle, and apoptosis. Despite the ubiquitous distribution of the proteasome and its putative essential function, proteasome inhibitors have been developed that can be safely administered with acceptable side effects. Importantly, these compounds have been found to possess anti tumor activity and are presently incorporated into the treatment of multiple myeloma and mantle cell lymphoma. In 2003, bortezomib (velcade) was thefirst compound in this category to have received FDA approval. The mechanisms for the antitumor activity of bortezomib and related drugs remain elusive. NF-κB inhibition by proteasome inhibitors may play a role in some instances. Recently, terminally differentiated plasma cells have been shown to down regulate proteasome expression and overall proteasome activity, which may account for the exquisite susceptibility of multiple myeloma cells to proteasome inhibition. New proteasome inhibitors with improved pharmacological properties are being developed and will soon enter clinical experimentation. Finally, studies addressing the usefulness ofthese compounds in other types of malignancies are ongoing and may soon expand the number of applications of these new therapeutic agents.

AB - Proteasomal degradation is the main mechanism accounting for intracellular protein degradation. Not only is the proteasome involved in physiological protein turnover it is also calledintoplay by processes such as signal transduction, cell cycle, and apoptosis. Despite the ubiquitous distribution of the proteasome and its putative essential function, proteasome inhibitors have been developed that can be safely administered with acceptable side effects. Importantly, these compounds have been found to possess anti tumor activity and are presently incorporated into the treatment of multiple myeloma and mantle cell lymphoma. In 2003, bortezomib (velcade) was thefirst compound in this category to have received FDA approval. The mechanisms for the antitumor activity of bortezomib and related drugs remain elusive. NF-κB inhibition by proteasome inhibitors may play a role in some instances. Recently, terminally differentiated plasma cells have been shown to down regulate proteasome expression and overall proteasome activity, which may account for the exquisite susceptibility of multiple myeloma cells to proteasome inhibition. New proteasome inhibitors with improved pharmacological properties are being developed and will soon enter clinical experimentation. Finally, studies addressing the usefulness ofthese compounds in other types of malignancies are ongoing and may soon expand the number of applications of these new therapeutic agents.

KW - Apoptosis

KW - Cancer

KW - Multiple myeloma

KW - NF-κB

KW - Proteasome inhibitors

UR - http://www.scopus.com/inward/record.url?scp=36749050889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749050889&partnerID=8YFLogxK

M3 - Article

C2 - 17935285

AN - SCOPUS:36749050889

VL - 12

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - SUPPL. 1

ER -